Viewpoint: necroptosis influences the type of liver cancer via changes of hepatic microenvironment.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Prognostic model for hepatocellular carcinoma based on necroptosis-related genes and analysis of drug treatment responses.Heliyon · 2024
   Article
2. Programmed Cell Death Pathways in Cholangiocarcinoma: Opportunities for Targeted Therapy.Cancers · 2023
   Review
3. Construction and validation of a prognostic signature based on necroptosis-related genes in hepatocellular carcinoma.PloS one · 2023
   Article
4. Identification and Validation of Necroptosis-Related LncRNA Signature in Hepatocellular Carcinoma for Prognosis Estimation and Microenvironment Status.Frontiers in genetics · 2022
   Article
5. Necroptosis in Cholangiocarcinoma.Cells · 2020
   Review

Corrections and comments

• Comment on
  Necroptosis microenvironment directs lineage commitment in liver cancer.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.